R Tandon

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. ncbi Efficacy of newer generation antipsychotics in the treatment of schizophrenia
    R Tandon
    University of Michigan Hospital, 1500 E Medical Center Drive, Department of Psychiatry, UH9C 9150, Ann Arbor, MI 48109 0120, USA
    Psychoneuroendocrinology 28:9-26. 2003
  2. ncbi Improvement without impairment: a review of clinical data for quetiapine in the treatment of schizophrenia
    Rajiv Tandon
    University of Michigan Medical Center, Ann Arbor, 48109 0120, USA
    J Clin Psychopharmacol 23:S15-20. 2003
  3. ncbi Suicidal behavior in schizophrenia
    Rajiv Tandon
    Department of Children and Families, Office of Mental Health, State of Florida, USA
    Expert Rev Neurother 5:95-9. 2005
  4. ncbi The second-generation 'atypical' antipsychotics: similar improved efficacy but different neuroendocrine side effects
    R Tandon
    University of Michigan Hospital, 1500 E Medical Center Drive, Department of Psychiatry, UH9C 9150, Ann Arbor, MI 48109 0120, USA
    Psychoneuroendocrinology 28:1-7. 2003
  5. ncbi Safety and tolerability: how do newer generation "atypical" antipsychotics compare?
    Rajiv Tandon
    University of Michigan Medical Center, Ann Arbor, MI 48109 0120, USA
    Psychiatr Q 73:297-311. 2002
  6. ncbi Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome
    Rajiv Tandon
    University of Michigan, Ann Arbor, USA
    Ann Clin Psychiatry 14:123-9. 2002
  7. ncbi World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia
    Rajiv Tandon
    University of Florida, Tallahassee, USA
    Schizophr Res 100:20-38. 2008
  8. ncbi Schizophrenia, "Just the Facts": what we know in 2008 part 1: overview
    Rajiv Tandon
    University of Florida, 3706 Glin Circle, Tallahassee, FL 32309, United States
    Schizophr Res 100:4-19. 2008
  9. ncbi Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome
    R Tandon
    Schizophrenia Program, University of Michigan Health System, 1500 E Medical Center Drive, Ann Arbor, MI, 48109 0120, USA
    Schizophr Res 45:191-201. 2000
  10. ncbi Antipsychotics from theory to practice: integrating clinical and basic data
    R Tandon
    University of Michigan Medical Center, Ann Arbor 48109 0120, USA
    J Clin Psychiatry 60:21-8. 1999

Detail Information

Publications40

  1. ncbi Efficacy of newer generation antipsychotics in the treatment of schizophrenia
    R Tandon
    University of Michigan Hospital, 1500 E Medical Center Drive, Department of Psychiatry, UH9C 9150, Ann Arbor, MI 48109 0120, USA
    Psychoneuroendocrinology 28:9-26. 2003
    ..While data thus far do not support assertions of differential efficacy between risperidone, olanzapine, and quetiapine, there are clear differences in their side-effect profiles and these are briefly summarized...
  2. ncbi Improvement without impairment: a review of clinical data for quetiapine in the treatment of schizophrenia
    Rajiv Tandon
    University of Michigan Medical Center, Ann Arbor, 48109 0120, USA
    J Clin Psychopharmacol 23:S15-20. 2003
    ..The favorable overall effectiveness of quetiapine suggests it is well suited for the long-term treatment of patients with psychotic disorders...
  3. ncbi Suicidal behavior in schizophrenia
    Rajiv Tandon
    Department of Children and Families, Office of Mental Health, State of Florida, USA
    Expert Rev Neurother 5:95-9. 2005
    ..Over the past 10 years, much has been learnt and hopefully this momentum will be translated into increasingly better outcomes...
  4. ncbi The second-generation 'atypical' antipsychotics: similar improved efficacy but different neuroendocrine side effects
    R Tandon
    University of Michigan Hospital, 1500 E Medical Center Drive, Department of Psychiatry, UH9C 9150, Ann Arbor, MI 48109 0120, USA
    Psychoneuroendocrinology 28:1-7. 2003
    ..A critical overview of neuroendocrine abnormalities in schizophrenia is provided and the differential impact of different antipsychotics in contributing to neuroendocrine dysfunction is discussed...
  5. ncbi Safety and tolerability: how do newer generation "atypical" antipsychotics compare?
    Rajiv Tandon
    University of Michigan Medical Center, Ann Arbor, MI 48109 0120, USA
    Psychiatr Q 73:297-311. 2002
    ....
  6. ncbi Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome
    Rajiv Tandon
    University of Michigan, Ann Arbor, USA
    Ann Clin Psychiatry 14:123-9. 2002
    ..Clinically, this EPS advantage of atypical antipsychotics translates into several important benefits, including better negative symptom efficacy, less dysphoria, less impaired cognition, a lower risk of TD, and better overall outcome...
  7. ncbi World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia
    Rajiv Tandon
    University of Florida, Tallahassee, USA
    Schizophr Res 100:20-38. 2008
    ....
  8. ncbi Schizophrenia, "Just the Facts": what we know in 2008 part 1: overview
    Rajiv Tandon
    University of Florida, 3706 Glin Circle, Tallahassee, FL 32309, United States
    Schizophr Res 100:4-19. 2008
    ..We intend to follow this paper with the submission to the journal of a series of topic-specific articles, critically reviewing the evidence...
  9. ncbi Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome
    R Tandon
    Schizophrenia Program, University of Michigan Health System, 1500 E Medical Center Drive, Ann Arbor, MI, 48109 0120, USA
    Schizophr Res 45:191-201. 2000
    ..These data suggest that phasic negative symptoms and enduring negative symptoms may be caused by different pathophysiological mechanisms...
  10. ncbi Antipsychotics from theory to practice: integrating clinical and basic data
    R Tandon
    University of Michigan Medical Center, Ann Arbor 48109 0120, USA
    J Clin Psychiatry 60:21-8. 1999
    ..After a comparative overview of their receptor-binding profiles, a brief pharmacokinetic summary will be provided. Finally, the clinical profiles of these agents will be summarized with regard to both their efficacy and adverse effects...
  11. ncbi Schizophrenia, "just the facts" 4. Clinical features and conceptualization
    Rajiv Tandon
    Department of Psychiatry, University of Florida College of Medicine, P O Box 100256, Gainesville, FL 32610, USA
    Schizophr Res 110:1-23. 2009
    ..Possible implications for DSM-V and ICD-11 definitions of schizophrenia are discussed...
  12. ncbi Hippocampus and amygdala in schizophrenia: assessment of the relationship of neuroanatomy to psychopathology
    R Rajarethinam
    Department of Psychiatry, PBMP, Wayne State University, 2751 E Jefferson, Suite 200, Room 265, Detroit, MI 48207, USA
    Psychiatry Res 108:79-87. 2001
    ..Our findings further support the role of the HAC in the pathophysiology of schizophrenia and suggest unique associations between individual structures and specific symptoms of the illness...
  13. ncbi Biological predictors of 1-year outcome in schizophrenia in males and females
    M Goldman
    Department of Psychiatry, University of Michigan Medical Center, Ann Arbor 48109 0116, USA
    Schizophr Res 21:65-73. 1996
    ..The findings underscore the importance of considering gender differences in studies of schizophrenia...
  14. ncbi Effects of antipsychotic treatment on polysomnographic measures in schizophrenia: a replication and extension
    S Maixner
    Schizophrenia Program, University of Michigan Medical Center, Ann Arbor 48109 0120, USA
    Am J Psychiatry 155:1600-2. 1998
    ..The authors sought to replicate and extend previous observations of improvement in some EEG sleep measures during the course of antipsychotic treatment in schizophrenia patients...
  15. ncbi Stability of positive and negative symptom constructs during neuroleptic treatment in schizophrenia
    R S Goldman
    Schizophrenia Program, University of Michigan Medical Center, Ann Arbor
    Psychopathology 24:247-52. 1991
    ..The findings suggest that BPRS-positive symptom items and the SANS measure distinct clinical dimensions and that the construct is stable, as demonstrated by minimal structural change with time...
  16. ncbi Combined electroconvulsive therapy and clozapine in treatment-resistant schizophrenia
    H C Kales
    Division of Geriatric Psychiatry, University of Michigan, Ann Arbor, USA
    Prog Neuropsychopharmacol Biol Psychiatry 23:547-56. 1999
    ..The long-term impact of ECT on the course of schizophrenia in patients incompletely responsive to clozapine is not fully elucidated...
  17. ncbi New atypical antipsychotic medications
    M D Jibson
    Department of Psychiatry, University of Michigan School of Medicine, Ann Arbor 48109 0120, USA
    J Psychiatr Res 32:215-28. 1998
    ..Further refinement of our understanding of the clinical utility of these drugs awaits their widespread use in mainstream clinical settings. Controlled studies comparing them to one another should be of particular interest...
  18. ncbi Does neuroanatomy predict ECT response?
    J R DeQuardo
    University of Michigan ECT Program, Department of Psychiatry, Ann Arbor, USA
    Prog Neuropsychopharmacol Biol Psychiatry 21:1339-52. 1997
    ....
  19. ncbi Treatment guidelines for depression in pregnancy
    S M Marcus
    Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA
    Int J Gynaecol Obstet 72:61-70. 2001
    ..This paper provides current treatment guidelines to aid in appropriate diagnosis and treatment of depression in pregnancy and postpartum. Review of current literature on psychotropic medication use in pregnancy is also provided...
  20. ncbi Comparison of central and peripheral pharmacologic effects of biperiden and trihexyphenidyl in human volunteers
    S K Guthrie
    College of Pharmacy and Department of Psychiatry, The University of Michigan, Ann Arbor 48109 1065, USA
    J Clin Psychopharmacol 20:77-83. 2000
    ..The results of this study do not support the hypothesis that the side effect profile of biperiden is significantly different from that of trihexyphenidyl...
  21. ncbi Beyond the facts in schizophrenia: closing the gaps in diagnosis, pathophysiology, and treatment
    H Nasrallah
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45244, USA
    Epidemiol Psychiatr Sci 20:317-27. 2011
    ....
  22. ncbi Cholinergic syndrome following anticholinergic withdrawal in a schizophrenic patient abusing marijuana
    R Tandon
    Schizophrenia Program, University of Michigan Medical Center, Ann Arbor 48109 0120
    Br J Psychiatry 154:712-4. 1989
    ..The clinical distinction between a cholinergic overdrive state and schizophrenic exacerbation, while sometimes difficult, can be critical in selecting appropriate management...
  23. ncbi The effect of paroxetine on thiothixene pharmacokinetics
    S K Guthrie
    College of Pharmacy, University of Michigan, Ann Arbor 48109 1065, USA
    J Clin Pharm Ther 22:221-6. 1997
    ..In this study healthy volunteers received thiothixene with and without a 3-day pretreatment with paroxetine to determine if paroxetine decreased the clearance of thiothixene...
  24. ncbi Sleep architecture and sleep apnea in patients with Cushing's disease
    J E Shipley
    Department of Psychiatry, University of Michigan, Ann Arbor 48109-0840
    Sleep 15:514-8. 1992
    ....
  25. ncbi Prevalence of cavum septum pellucidum in schizophrenia studied with MRI
    R Rajarethinam
    Schizophrenia Research Program, University of Michigan Hospitals, 1500 East Medical Center Drive, 48109, Ann Arbor, MI, USA
    Schizophr Res 48:201-5. 2001
    ..CONCLUSION: Higher incidence of CSP may reflect a neurodevelopmental disturbance in schizophrenia...
  26. ncbi ECT and mental retardation: a review and case reports
    M Aziz
    Department of Psychiatry, University of Michigan, Ann Arbor 48109, USA
    J ECT 17:149-52. 2001
    ..We conclude that ECT can be used safely and effectively in patients with mental retardation and severe or refractory psychotic symptoms...
  27. ncbi Quetiapine has a direct effect on the negative symptoms of schizophrenia
    Rajiv Tandon
    State of Florida, Department of Children and Families, 1317 Winewood Blvd, Bldg 6, Room 235, Tallahassee, FL 32399, USA
    Hum Psychopharmacol 19:559-63. 2004
    ..Within the constraints of the path analysis methodology, these results indicate that quetiapine has a substantial direct effect on improving the negative symptoms of schizophrenia...
  28. ncbi First- and second-generation antipsychotics: learning from CUtLASS and CATIE
    Rajiv Tandon
    Arch Gen Psychiatry 64:977-8; author reply 979-80. 2007
  29. ncbi Subjecting meta-analyses to closer scrutiny: Little support for differential efficacy among second-generation antipsychotics at equivalent doses
    Rajiv Tandon
    Arch Gen Psychiatry 63:935-7; author reply 937-9. 2006
  30. ncbi Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia
    Henry A Nasrallah
    Department of Psychiatry, University of Mississippi Medical Center, Jackson, Miss, USA
    J Clin Psychiatry 63:12-20. 2002
    ..This article will review the clinical trials examining the efficacy, safety, and tolerability of quetiapine in the treatment of patients with schizophrenia...
  31. ncbi Defining and measuring clinical effectiveness in the treatment of schizophrenia
    Henry A Nasrallah
    Department of Psychiatry, University of Cincinnati Medical Center, Cincinnati, Ohio 45267 0559, USA
    Psychiatr Serv 56:273-82. 2005
    ..This report describes an approach to define and measure the clinical effectiveness of treatment in achieving these objectives...
  32. ncbi Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder
    Rajiv Tandon
    Department of Psychiatry (Adjunct, University of Florida, Gainesville, FL, USA
    Psychiatry Res 136:211-21. 2005
    ..35 days in the study and a decrease in CGI-I of 0.21 units. These results provide initial validation of the IAQ as a tool for evaluating antipsychotic response in patients with schizophrenia or schizoaffective disorder...
  33. ncbi Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment
    Rajiv Tandon
    Office of Mental Health, Department of Children and Families, State of Florida, 1317 Winewood Boulevard, Tallahassee, FL 32399 0700, USA
    Schizophr Res 79:145-55. 2005
    ..Dosing appears to be a critical variable in optimizing efficacy...
  34. ncbi A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA)
    Rajiv Tandon
    Florida Department of Children and Families, 1317 Winewood Boulevard, Tallahassee, FL 32399, USA
    Schizophr Res 84:77-89. 2006
    ..BETA was designed to evaluate the overall effectiveness of aripiprazole in patients with schizophrenia or schizoaffective disorder treated in a general psychiatry outpatient practice setting...
  35. ncbi Antipsychotic treatment of schizophrenia: two steps forward, one step back
    Rajiv Tandon
    Curr Psychiatry Rep 9:263-4. 2007
  36. ncbi Impact of the CATIE findings on state mental health policy
    Joseph J Parks
    Missouri Department of Mental Health, Jefferson City, MO 65102, USA
    Psychiatr Serv 59:534-6. 2008
    ..Third, more resources should be invested in clinical trials that more clearly and accurately reflect current practice...
  37. ncbi Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology
    Rajiv Tandon
    University of Florida, 3706 Glin Circle, Tallahassee, FL 32309, United States
    Schizophr Res 102:1-18. 2008
    ..The ability to question some of our basic assumptions about the etiology and nature of schizophrenia and greater rigor in its study appear critical to improving our understanding about its causation...
  38. ncbi Do SSRIs or antidepressants in general increase suicidality? WPA Section on Pharmacopsychiatry: consensus statement
    Hans Jurgen Moller
    Department of Psychiatry, Ludwig Maximilians University Munchen, Nussbaumstrasse 7, 80336 Munich, Germany
    Eur Arch Psychiatry Clin Neurosci 258:3-23. 2008
    ..It is the major problem facing efforts to identify the possible 'suicidal effects' of antidepressants...
  39. ncbi Strategies for maximizing clinical effectiveness in the treatment of schizophrenia
    Rajiv Tandon
    Florida Department of Children and Families, Tallahassee, FL 32399, USA
    J Psychiatr Pract 12:348-63. 2006
    ..Finally, the effectiveness of providing optimal individualized treatment/rehabilitation is best gauged by measuring progress on multiple effectiveness domains. Approaches for efficient and reliable assessment are discussed...
  40. ncbi Comparing antipsychotic efficacy
    Rajiv Tandon
    Am J Psychiatry 163:1645. 2006